Immunome Inc. (IMNM) Form 8-K — Aug 11, 2026
Immunome reported a second-quarter 2026 net loss of $73.1 million, or $0.65 per share, versus a $43.4 million loss ($0.50 per share) in the year-ago quarter, as R&D spending rose to $59.9 million and G&A to $18.3 million. Cash, cash equivalents and marketable securities totaled $520.0 million at June 30, 2026, which management expects to fund operations into 2028. Collaboration revenue was zero versus $4.0 million a year ago. The FDA accepted the varegacestat NDA in adults with desmoid tumors and set a PDUFA target action date of April 28, 2027.
Key figures
- Revenue
- 0
- Guidance
- Current cash position expected to fund operations into 2028
- Net Income
- -$73.1 million
- Cash Position
- $520.0 million
- Pdufa Date
- April 28, 2027
- Cash Runway
- into 2028
- Hazard Ratio
- 0.16
- Orr Varegacestat
- 56% vs 9% placebo
- Ga Expense Q2 2026
- $18.3 million
- Prior Year Net Loss
- -$43.4 million
- Rnd Expense Q2 2026
- $59.9 million
- Progression Risk Reduction
- 84%
- Weighted Avg Shares Q2 2026
- 113272931
- Prior Year Collaboration Revenue
- $4.0 million
Price after filing
Close on the filing date to close N calendar days later (from $25.69). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.